KISQALI 200MG

Description

Kisqali belongs to biological therapy.

This group of drugs stops the development and spread of cancer. They target and prohibits processes in the cells which cause cancer to grow. When required to treat breast cancer, Kisqali is taken alongside hormone (endocrine) therapy.

Kisqali is a prescription drugs provided under guidance of doctors

Indication

Kisqali 200mg is used in combination with letrozole which an aromatase inhibitor for the treatment for women with breast cancer

Dosage and administration

The usual dose of Kisqali is 600mg (three 200mg film coated tablets) administrated orally once daily for 21 consecutive days followed by 7 days off therapy resulting in a complete cycle of 28 days

The drug Kisqali can be administrated with or without food.

Overdose: overdose with Kisqali in human has experienced very limited. In case occurs provide general symptomatic and supportive measures.

Mechanism of action

Some proteins in the body leads cells to develop and divide. In ER positive (ER+), HER2 negative breast cancer, these proteins can become overactive and producebreast cancer cells to grow. Ribociclib works by stopping these proteins, helping to discontinue the cancer cells growing and dividing.

When interaction with hormone treatmentwhichinhibits the effects of oestrogen on cancer cells, Ribociclib helps to delay the growth of ER+, HER2 negative breast cancer.

Pharmacokinetics Properties

Absorption: Time to maximum plasma concentration is 1-4 hr and steady state achieved is 8 days

Distribution: Human plasma protein bound is 70%

Metabolism: Mainly metabolised by hepatic through CYP3A4 in humans

Elimination: Kisqali is eliminated through feces 69% and urine 23%

Half -life is 32.6 hours

Side effects

Reduction in blood counts

Nausea and vomiting

Increased liver enzymes

Fatigue

Diarrhea

Hair loss

Reduced kidney function

Lack of appetite

Rash

Fever

Itching

Insomnia

Urinary tract infection

Drug interaction

Midazolam Co administrationwith multiple doses of Kisqali will increased the midazolam exposure by 3.8-fold in healthy subjects.

Kisqali 200mg combination with strong CYP3A4 inhibitor will increased Ribociclib exposure in healthy subjects but this combination cannot be avoided, so reduce the dose of Kisqali to 400mg once daily

Kisqali 200mg interaction with strong CYP3A4 inducers will decreased Ribociclib exposure in healthy subjects by 89%

Contraindication

None

Precautions

Kisqali has been exposed to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during therapy, Kisqali may needed dose interruption, reduction, or discontinuation.

Do not use the combination with tamoxifen due to increased QT prolongation.

In patients with advanced or metastatic breast cancer will increases in transaminases were resulted; perform liver function test before starting treatment with Kisqali; based on severity of the transaminase elevations, Kisqali may require dose interference, reduction or stopping.

Pregnancy

There are no studies with the use of Kisqali in pregnant women to inform drug-along with risks. Hence avoid becoming pregnancy during Jakavi 5mg treatment

Lactation

Avoid breast feeding during treatment with Kisqali. Excretion into human milk is unknown

Storage

The drug Kisqali is store at 20⁰C to 25⁰C

Missed dose

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule.

Must Consult doctors regarding missed dose.